Ayse Seda Yazgili
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayse Seda Yazgili has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Silke Meiners
Forschungszentrum Borstel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Sülfeld, Germany
6 shared publications Thomas Meul
Comprehensive Pneumology Center (CPC), University Hospital of the Ludwig-Maximilians-University (LMU) and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL) 1 , Max-Lebsche Platz 31, 81377 Munich
5 shared publicationsChristina Lukas
Comprehensive Pneumology Center (CPC), University Hospital of the Ludwig-Maximilians-University (LMU) and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Max-Lebsche Platz 31, 81377, München, Germany
4 shared publicationsSilke Meiners
Comprehensive Pneumology Center (CPC), Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum Munich, Munich, Germany
3 shared publicationsVanessa Welk
Comprehensive Pneumology Center (CPC), University Hospital of the Ludwig-Maximilians-University (LMU) and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Max-Lebsche Platz 31, 81377, München, Germany
3 shared publicationsElvira Stacher-Priehse
Asklepios Lung Clinic Munich-Gauting, 82131, Gauting, Germany
2 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8175
PA200 modulates immunoproteasome structure and activity
The proteasome activator PA200 binds to the catalytic core of both standard proteasome (s20S) and the immunoproteasome (i20S); however, whether PA200 uses the same mechanisms to activate i20S remains unknown. In this work, the cryo-EM structures of singly- and doubly-capped i20S–PA200 complexes, combined with complementary in vitro biochemical assays, show that binding of the first PA200 induces allosteric bending of the i20S and widens the opposite α-ring, promoting higher PA200 occupancy and stronger activation compared to the s20S. PA200 also selectively modulates i20S proteolytic activity by enhancing peptide production and shifting cleavage specificity toward caspase-like activity. In cells and tissues co-expressing PA200, s20S, and i20S, PA200 preferentially associates with the i20S. Moreover, PA200 and i20S catalytic subunits are differentially regulated, with PA200 playing a potential role in regulating the i20S subunits’ expression. Overall, these findings suggest that PA200 contributes to the regulation of i20S function and dynamics.
- 11 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8175
Open AccessPA200 modulates immunoproteasome structure and activity
The proteasome activator PA200 binds to the catalytic core of both standard proteasome (s20S) and the immunoproteasome (i20S); however, whether PA200 uses the same mechanisms to activate i20S remains unknown. In this work, the cryo-EM structures of singly- and doubly-capped i20S–PA200 complexes, combined with complementary in vitro biochemical assays, show that binding of the first PA200 induces allosteric bending of the i20S and widens the opposite α-ring, promoting higher PA200 occupancy and stronger activation compared to the s20S. PA200 also selectively modulates i20S proteolytic activity by enhancing peptide production and shifting cleavage specificity toward caspase-like activity. In cells and tissues co-expressing PA200, s20S, and i20S, PA200 preferentially associates with the i20S. Moreover, PA200 and i20S catalytic subunits are differentially regulated, with PA200 playing a potential role in regulating the i20S subunits’ expression. Overall, these findings suggest that PA200 contributes to the regulation of i20S function and dynamics.
- 15 February 2026
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 139 (4)
PA200 differentially regulates the proteasome and inhibits migration of NSCLC cells
Proteasome activator 200 (PA200; also known as PSME4) is upregulated in non-small cell lung cancer (NSCLC) and linked to poor prognosis. We have previously demonstrated that the overexpression of PA200 in NSCLC is associated with immune evasion and reduced responsiveness to immune checkpoint inhibitors. The cell autonomous function of PA200 in cancer growth, however, has not been solved. We here demonstrate that deletion of PA200 in two distinct lung cancer cell lines induced cell-specific alterations in proteasome composition and activities with a minor direct impact on overall proteasome activity. Deficiency of PA200 in lung cancer cells did not consistently alter tumor cell growth in vitro and in vivo. However, we observed concerted inhibition of tumor cell migration and invasion with conserved downregulation of the integrin ITGB3 and transcriptional dysregulation of multiple cell adhesion and extracellular matrix regulators. Our transcriptome profiling revealed a striking disparity in the transcriptional response to PA200 deletion in the two lung cancer cell lines. Together with our PA200 interactome analysis that uncovered an unexpected cell-dependent profile of PA200-interacting proteins, our data indicate that the function of PA200 is cell specific and depends on the cellular context. In conclusion, we here demonstrate that PA200 cell-autonomously regulates the invasive capacities of tumor cells thereby potentially promoting lung cancer spread and metastasis formation. This mechanism might add to PA200-related immune evasion and contribute to the observed poor prognosis of individuals with PA200-overexpressing lung cancer.
- 15 February 2026
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 139 (4)
PA200 differentially regulates the proteasome and inhibits migration of NSCLC cells
Proteasome activator 200 (PA200; also known as PSME4) is upregulated in non-small cell lung cancer (NSCLC) and linked to poor prognosis. We have previously demonstrated that the overexpression of PA200 in NSCLC is associated with immune evasion and reduced responsiveness to immune checkpoint inhibitors. The cell autonomous function of PA200 in cancer growth, however, has not been solved. We here demonstrate that deletion of PA200 in two distinct lung cancer cell lines induced cell-specific alterations in proteasome composition and activities with a minor direct impact on overall proteasome activity. Deficiency of PA200 in lung cancer cells did not consistently alter tumor cell growth in vitro and in vivo. However, we observed concerted inhibition of tumor cell migration and invasion with conserved downregulation of the integrin ITGB3 and transcriptional dysregulation of multiple cell adhesion and extracellular matrix regulators. Our transcriptome profiling revealed a striking disparity in the transcriptional response to PA200 deletion in the two lung cancer cell lines. Together with our PA200 interactome analysis that uncovered an unexpected cell-dependent profile of PA200-interacting proteins, our data indicate that the function of PA200 is cell specific and depends on the cellular context. In conclusion, we here demonstrate that PA200 cell-autonomously regulates the invasive capacities of tumor cells thereby potentially promoting lung cancer spread and metastasis formation. This mechanism might add to PA200-related immune evasion and contribute to the observed poor prognosis of individuals with PA200-overexpressing lung cancer.
- Open Access
- 24 November 2025
- Published by Springer Nature in Nature
- Vol. 650 (8102) , 748-758
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance
The colorectal epithelium is rapidly renewing, with remarkable capacity to regenerate following injury. In colorectal cancer (CRC), this regenerative capacity can be co-opted to drive epithelial plasticity. Although oncogenic MAPK signalling in CRC is common, with frequent mutations of both KRAS (40–50%) and BRAF (10%) 1 , inhibition of this pathway typically drives resistance clinically. Here, given the development of KRAS inhibitors and licensing of BRAF inhibitor combinations 2–4 , we have interrogated key mechanisms of resistance to these agents in advanced preclinical CRC models. We show that oncogenic MAPK signalling induces epithelial-state changes in vivo, driving adoption of a regenerative/revival stem-like population, whereas inhibition leads to rapid transcriptional remodelling of both Kras -mutant and Braf- mutant tumours, favouring a WNT-associated, canonical stem phenotype. This drives acute therapeutic resistance in Kras -driven and delayed resistance in Braf -driven models. Where plasticity is restrained, such as in early metastatic disease, or through targeting ligand-dependent WNT pathway Rnf43 mutations, marked therapeutic responses are observed. This explains the super response to BRAF + EGFR-targeted therapies previously observed in a BRAF–RNF43 co-mutant patient population, highlighting the criticality of cellular plasticity in therapeutic response. Together, our data provide clear insight into the mechanisms underpinning resistance to MAPK-targeted therapies in CRC. Moreover, strategies that aim to corral stem cell fate, restrict epithelial plasticity or intervene when tumours lack heterogeneity may improve therapeutic efficacy of these agents.
- 24 November 2025
- Published by Springer Nature in Nature
- Vol. 650 (8102) , 748-758
Open AccessMAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance
The colorectal epithelium is rapidly renewing, with remarkable capacity to regenerate following injury. In colorectal cancer (CRC), this regenerative capacity can be co-opted to drive epithelial plasticity. Although oncogenic MAPK signalling in CRC is common, with frequent mutations of both KRAS (40–50%) and BRAF (10%) 1 , inhibition of this pathway typically drives resistance clinically. Here, given the development of KRAS inhibitors and licensing of BRAF inhibitor combinations 2–4 , we have interrogated key mechanisms of resistance to these agents in advanced preclinical CRC models. We show that oncogenic MAPK signalling induces epithelial-state changes in vivo, driving adoption of a regenerative/revival stem-like population, whereas inhibition leads to rapid transcriptional remodelling of both Kras -mutant and Braf- mutant tumours, favouring a WNT-associated, canonical stem phenotype. This drives acute therapeutic resistance in Kras -driven and delayed resistance in Braf -driven models. Where plasticity is restrained, such as in early metastatic disease, or through targeting ligand-dependent WNT pathway Rnf43 mutations, marked therapeutic responses are observed. This explains the super response to BRAF + EGFR-targeted therapies previously observed in a BRAF–RNF43 co-mutant patient population, highlighting the criticality of cellular plasticity in therapeutic response. Together, our data provide clear insight into the mechanisms underpinning resistance to MAPK-targeted therapies in CRC. Moreover, strategies that aim to corral stem cell fate, restrict epithelial plasticity or intervene when tumours lack heterogeneity may improve therapeutic efficacy of these agents.
- 24 November 2022
- Published by Springer Nature in Nature Neuroscience
- Vol. 25 (12) , 1608-1625
TDP-43 condensates and lipid droplets regulate the reactivity of microglia and regeneration after traumatic brain injury
Decreasing the activation of pathology-activated microglia is crucial to prevent chronic inflammation and tissue scarring. In this study, we used a stab wound injury model in zebrafish and identified an injury-induced microglial state characterized by the accumulation of lipid droplets and TAR DNA-binding protein of 43 kDa (TDP-43)+ condensates. Granulin-mediated clearance of both lipid droplets and TDP-43+ condensates was necessary and sufficient to promote the return of microglia back to the basal state and achieve scarless regeneration. Moreover, in postmortem cortical brain tissues from patients with traumatic brain injury, the extent of microglial activation correlated with the accumulation of lipid droplets and TDP-43+ condensates. Together, our results reveal a mechanism required for restoring microglia to a nonactivated state after injury, which has potential for new therapeutic applications in humans.
- 24 November 2022
- Published by Springer Nature in Nature Neuroscience
- Vol. 25 (12) , 1608-1625
TDP-43 condensates and lipid droplets regulate the reactivity of microglia and regeneration after traumatic brain injury
Decreasing the activation of pathology-activated microglia is crucial to prevent chronic inflammation and tissue scarring. In this study, we used a stab wound injury model in zebrafish and identified an injury-induced microglial state characterized by the accumulation of lipid droplets and TAR DNA-binding protein of 43 kDa (TDP-43)+ condensates. Granulin-mediated clearance of both lipid droplets and TDP-43+ condensates was necessary and sufficient to promote the return of microglia back to the basal state and achieve scarless regeneration. Moreover, in postmortem cortical brain tissues from patients with traumatic brain injury, the extent of microglial activation correlated with the accumulation of lipid droplets and TDP-43+ condensates. Together, our results reveal a mechanism required for restoring microglia to a nonactivated state after injury, which has potential for new therapeutic applications in humans.
- Open Access
- 20 August 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (8) , 1150
The Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease
Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases. Several proteasome inhibitors are approved for treating hematological cancers. However, their side effects impede their efficacy and broader therapeutic applications. Therefore, understanding the biology of the different proteasome complexes present in the cell is crucial for developing tailor-made inhibitors against specific proteasome complexes. Here, we will discuss the structure, biology, and function of the alternative Proteasome Activator 200 (PA200), also known as PSME4, and summarize the current evidence for its dysregulation in different human diseases. We hereby aim to stimulate research on this enigmatic proteasome regulator that has the potential to serve as a therapeutic target in cancer.
- 20 August 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (8) , 1150
Open AccessThe Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease
Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases. Several proteasome inhibitors are approved for treating hematological cancers. However, their side effects impede their efficacy and broader therapeutic applications. Therefore, understanding the biology of the different proteasome complexes present in the cell is crucial for developing tailor-made inhibitors against specific proteasome complexes. Here, we will discuss the structure, biology, and function of the alternative Proteasome Activator 200 (PA200), also known as PSME4, and summarize the current evidence for its dysregulation in different human diseases. We hereby aim to stimulate research on this enigmatic proteasome regulator that has the potential to serve as a therapeutic target in cancer.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA1133
LSC - 2021 - Regulation of PA200 in lung cancer
Lung cancer is the leading cause of death among all cancer types with the most common incidence and mortality rates. The proteasome is a well-identified therapeutic target for cancer treatment. It acts as the main protein degradation system in the cell and degrades key mediators of cell growth, migration and survival. In this study, we analyzed non-tumorous and tumor tissues of patients suffering from different types of lung cancers. We observed significant upregulation of proteasome activator 200 (PA200) in tumor tissues compared to non-tumor lung samples of the same patient (Mann-Whitney U test, n=6). We also analyzed tumor tissue sections of lung cancer patients by immunohistochemistry and showed that PA200 was strongly induced in cancer cells. However, neither tumor stroma nor necrotic areas indicated expression of the activator. Importantly, PA200 is significantly increased in lung adenocarcinoma (LUAD), squamous cell lung cancer (SQCLC) compared to small cell lung cancer (SCLC) and correlated with significantly diminished survival in non-small cell lung cancer patients. Silencing of PA200 in the lung adenoma cell line A549 resulted in concerted downregulation of invasion, proliferation and metastasis-related gene expression. Our future experiments will focus on the function of PA200 in lung cancer cell growth, migration and invasion using CRISPR/Cas9 PA200 depleted A549 and H1299 cell lines. We will investigate the cellular function of modified PA200/proteasome complexes by analyzing RNA and protein signatures via RNA sequencing and mass spectrometry, respectively. We will use the power of functional assays (migration and invasion assay, colony formation assay) and address the functional role of PA200 as an oncogenic regulator in lung tumor growth and metastasis in vitro.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA1133
LSC - 2021 - Regulation of PA200 in lung cancer
Lung cancer is the leading cause of death among all cancer types with the most common incidence and mortality rates. The proteasome is a well-identified therapeutic target for cancer treatment. It acts as the main protein degradation system in the cell and degrades key mediators of cell growth, migration and survival. In this study, we analyzed non-tumorous and tumor tissues of patients suffering from different types of lung cancers. We observed significant upregulation of proteasome activator 200 (PA200) in tumor tissues compared to non-tumor lung samples of the same patient (Mann-Whitney U test, n=6). We also analyzed tumor tissue sections of lung cancer patients by immunohistochemistry and showed that PA200 was strongly induced in cancer cells. However, neither tumor stroma nor necrotic areas indicated expression of the activator. Importantly, PA200 is significantly increased in lung adenocarcinoma (LUAD), squamous cell lung cancer (SQCLC) compared to small cell lung cancer (SCLC) and correlated with significantly diminished survival in non-small cell lung cancer patients. Silencing of PA200 in the lung adenoma cell line A549 resulted in concerted downregulation of invasion, proliferation and metastasis-related gene expression. Our future experiments will focus on the function of PA200 in lung cancer cell growth, migration and invasion using CRISPR/Cas9 PA200 depleted A549 and H1299 cell lines. We will investigate the cellular function of modified PA200/proteasome complexes by analyzing RNA and protein signatures via RNA sequencing and mass spectrometry, respectively. We will use the power of functional assays (migration and invasion assay, colony formation assay) and address the functional role of PA200 as an oncogenic regulator in lung tumor growth and metastasis in vitro.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA1127
Regulation of PA200 in lung cancer
Lung cancer is the leading cause of death among all cancer types with the most common incidence and mortality rates. The proteasome is a well-identified therapeutic target for cancer treatment. It acts as the main protein degradation system in the cell and degrades key mediators of cell growth, migration and survival. In this study, we analyzed the non-tumorous and tumour tissues of patients suffering from different types of lung cancers. We observed significant upregulation of proteasome activator 200 (PA200) in tumour tissues compared to non-tumour lung samples of the same patient (Mann-Whitney U test, n=6). We also analyzed tumour tissue sections of lung cancer patients by immunohistochemistry and showed that PA200 was strongly induced in cancer cells. However, neither tumour stroma nor necrotic areas indicated expression of the activator. Importantly, PA200 is significantly increased in lung adenocarcinoma (LUAD), squamous cell lung cancer (SQCLC) compared to small cell lung cancer (SCLC) and correlated with significantly diminished survival in non-small cell lung cancer patients. Silencing of PA200 in the lung adenoma cell line A549 resulted in concerted downregulation of invasion, proliferation and metastasis-related gene expression. Our future experiments will focus on the function of PA200 in lung cancer cell growth, migration and invasion using CRISPR/Cas9 PA200 depleted A549 and H1299 cell lines. We will investigate the cellular function of modified PA200/proteasome complexes by analyzing RNA and protein signatures via RNA sequencing and mass spectrometry, respectively. We will address the functional role of PA200 as an oncogenic regulator in lung tumour growth and metastasis in vitro.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA1127
Regulation of PA200 in lung cancer
Lung cancer is the leading cause of death among all cancer types with the most common incidence and mortality rates. The proteasome is a well-identified therapeutic target for cancer treatment. It acts as the main protein degradation system in the cell and degrades key mediators of cell growth, migration and survival. In this study, we analyzed the non-tumorous and tumour tissues of patients suffering from different types of lung cancers. We observed significant upregulation of proteasome activator 200 (PA200) in tumour tissues compared to non-tumour lung samples of the same patient (Mann-Whitney U test, n=6). We also analyzed tumour tissue sections of lung cancer patients by immunohistochemistry and showed that PA200 was strongly induced in cancer cells. However, neither tumour stroma nor necrotic areas indicated expression of the activator. Importantly, PA200 is significantly increased in lung adenocarcinoma (LUAD), squamous cell lung cancer (SQCLC) compared to small cell lung cancer (SCLC) and correlated with significantly diminished survival in non-small cell lung cancer patients. Silencing of PA200 in the lung adenoma cell line A549 resulted in concerted downregulation of invasion, proliferation and metastasis-related gene expression. Our future experiments will focus on the function of PA200 in lung cancer cell growth, migration and invasion using CRISPR/Cas9 PA200 depleted A549 and H1299 cell lines. We will investigate the cellular function of modified PA200/proteasome complexes by analyzing RNA and protein signatures via RNA sequencing and mass spectrometry, respectively. We will address the functional role of PA200 as an oncogenic regulator in lung tumour growth and metastasis in vitro.
- Open Access
- 1 June 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (2) , 100526
In-gel proteasome assay to determine the activity, amount, and composition of proteasome complexes from mammalian cells or tissues
- 1 June 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (2) , 100526
Open AccessIn-gel proteasome assay to determine the activity, amount, and composition of proteasome complexes from mammalian cells or tissues
- 11 March 2021
- Published by European Respiratory Society (ERS)
- Vol. 7 (suppl 6)
Regulation of PA200 in lung cancer
Lung cancer is the leading cause of death among all cancer types with the most common incidence and mortality rates. The proteasome is a well-identified therapeutic target for cancer treatment. It acts as the main protein degradation system in the cell and degrades key mediators of cell growth, migration and survival. In this study, we analyzed non-tumorous and tumor tissues of patients suffering from different types of lung cancers. We observed significant upregulation of proteasome activator 200 (PA200) in tumor tissues compared to non-tumor lung samples of the same patient (Mann-Whitney U test, n=6). We also analyzed tumor tissue sections of lung cancer patients by immunohistochemistry and showed that PA200 was strongly induced in cancer cells. However, neither tumor stroma nor necrotic areas indicated expression of the activator. Importantly, PA200 is significantly increased in lung adenocarcinoma (LUAD), squamous cell lung cancer (SQCLC) compared to small cell lung cancer (SCLC) and correlated with significantly diminished survival in non-small cell lung cancer patients. Silencing of PA200 in the lung adenoma cell line A549 resulted in concerted downregulation of invasion, proliferation and metastasis-related gene expression. Our future experiments will focus on the function of PA200 in lung cancer cell growth, migration and invasion using CRISPR/Cas9 PA200 depleted A549 and H1299 cell lines. We will investigate the cellular function of modified PA200/proteasome complexes by analyzing RNA and protein signatures via RNA sequencing and mass spectrometry, respectively. We will use the power of functional assays (migration and invasion assay, colony formation assay) and address the functional role of PA200 as an oncogenic regulator in lung tumor growth and metastasis in vitro.
- 11 March 2021
- Published by European Respiratory Society (ERS)
- Vol. 7 (suppl 6)
Regulation of PA200 in lung cancer
Lung cancer is the leading cause of death among all cancer types with the most common incidence and mortality rates. The proteasome is a well-identified therapeutic target for cancer treatment. It acts as the main protein degradation system in the cell and degrades key mediators of cell growth, migration and survival. In this study, we analyzed non-tumorous and tumor tissues of patients suffering from different types of lung cancers. We observed significant upregulation of proteasome activator 200 (PA200) in tumor tissues compared to non-tumor lung samples of the same patient (Mann-Whitney U test, n=6). We also analyzed tumor tissue sections of lung cancer patients by immunohistochemistry and showed that PA200 was strongly induced in cancer cells. However, neither tumor stroma nor necrotic areas indicated expression of the activator. Importantly, PA200 is significantly increased in lung adenocarcinoma (LUAD), squamous cell lung cancer (SQCLC) compared to small cell lung cancer (SCLC) and correlated with significantly diminished survival in non-small cell lung cancer patients. Silencing of PA200 in the lung adenoma cell line A549 resulted in concerted downregulation of invasion, proliferation and metastasis-related gene expression. Our future experiments will focus on the function of PA200 in lung cancer cell growth, migration and invasion using CRISPR/Cas9 PA200 depleted A549 and H1299 cell lines. We will investigate the cellular function of modified PA200/proteasome complexes by analyzing RNA and protein signatures via RNA sequencing and mass spectrometry, respectively. We will use the power of functional assays (migration and invasion assay, colony formation assay) and address the functional role of PA200 as an oncogenic regulator in lung tumor growth and metastasis in vitro.
- Open Access
- 1 August 2020
- Published by Elsevier in Cell Reports
- Vol. 32 (8) , 108059
Mitochondrial Regulation of the 26S Proteasome
- 1 August 2020
- Published by Elsevier in Cell Reports
- Vol. 32 (8) , 108059
Open AccessMitochondrial Regulation of the 26S Proteasome